Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04434196
Title A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

CC-99282 + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA | ESP | CAN | AUT


No variant requirements are available.